Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits.

van Veen HA, Koiter J, Vogelezang CJ, van Wessel N, van Dam T, Velterop I, van Houdt K, Kupers L, Horbach D, Salaheddine M, Nuijens JH, Mannesse ML.

J Biotechnol. 2012 Dec 31;162(2-3):319-26. doi: 10.1016/j.jbiotec.2012.09.005. Epub 2012 Sep 17.

PMID:
22995741
2.

Clinical impact of peripheral attacks in hereditary angioedema patients.

Kusuma A, Relan A, Knulst AC, Moldovan D, Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Hack CE.

Am J Med. 2012 Sep;125(9):937.e17-24. doi: 10.1016/j.amjmed.2011.12.016. Epub 2012 Jun 27.

3.

Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.

Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE.

J Allergy Clin Immunol. 2010 Oct;126(4):821-827.e14. doi: 10.1016/j.jaci.2010.07.021.

PMID:
20920772
4.

Characterization of bovine neutrophil gelatinase-associated lipocalin.

van Veen HA, Geerts ME, Zoetemelk RA, Nuijens JH, van Berkel PH.

J Dairy Sci. 2006 Sep;89(9):3400-7.

5.

Sub-chronic (13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of transgenic cows.

Appel MJ, van Veen HA, Vietsch H, Salaheddine M, Nuijens JH, Ziere B, de Loos F.

Food Chem Toxicol. 2006 Jul;44(7):964-73. Epub 2006 Jan 19.

PMID:
16426723
6.

The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin.

Thomassen EA, van Veen HA, van Berkel PH, Nuijens JH, Abrahams JP.

Transgenic Res. 2005 Aug;14(4):397-405.

PMID:
16201406
7.

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, De Carolis C, Drouet C, Duponchel C, Farkas H, Fáy K, Fekete B, Fischer B, Fontana L, Füst G, Giacomelli R, Gröner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmár L, Kaposi PN, Karádi I, Kitzinger A, Kollár T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Németh E, Nielsen EW, Nuijens JH, O'grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusicke E, Späth PJ, Szendei G, Takács E, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L.

J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51-131.

PMID:
15356535
8.

The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis.

van Veen HA, Geerts ME, van Berkel PH, Nuijens JH.

Eur J Biochem. 2004 Feb;271(4):678-84.

9.

N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits.

Koles K, van Berkel PH, Pieper FR, Nuijens JH, Mannesse ML, Vliegenthart JF, Kamerling JP.

Glycobiology. 2004 Jan;14(1):51-64. Epub 2003 Sep 26.

PMID:
14514717
10.

Analytical cation-exchange chromatography to assess the identity, purity, and N-terminal integrity of human lactoferrin.

van Veen HA, Geerts ME, van Berkel PH, Nuijens JH.

Anal Biochem. 2002 Oct 1;309(1):60-6.

PMID:
12381362
11.

Characterization of monoclonal antibodies against human lactoferrin.

van Berkel PH, van Veen HA, Geerts ME, Nuijens JH.

J Immunol Methods. 2002 Sep 15;267(2):139-50.

PMID:
12165435
12.

Large scale production of recombinant human lactoferrin in the milk of transgenic cows.

van Berkel PH, Welling MM, Geerts M, van Veen HA, Ravensbergen B, Salaheddine M, Pauwels EK, Pieper F, Nuijens JH, Nibbering PH.

Nat Biotechnol. 2002 May;20(5):484-7.

PMID:
11981562
13.

Does human lactoferrin in the milk of transgenic mice deliver iron to suckling neonates?

Hanson LH, Sawicki V, Lewis A, Nuijens JH, Neville MC, Zhang P.

Adv Exp Med Biol. 2001;501:233-9. Review.

PMID:
11787686
14.

Human lactoferrin in the milk of transgenic mice increases intestinal growth in ten-day-old suckling neonates.

Zhang P, Sawicki V, Lewis A, Hanson L, Nuijens JH, Neville MC.

Adv Exp Med Biol. 2001;501:107-13.

PMID:
11787671
15.

Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria.

Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK, Nuijens JH.

Infect Immun. 2001 Mar;69(3):1469-76.

16.

Charge modification of plasma and milk proteins results in antiviral active compounds.

Swart PJ, Harmsen MC, Kuipers ME, Van Dijk AA, Van Der Strate BW, Van Berkel PH, Nuijens JH, Smit C, Witvrouw M, De Clercq E, de Béthune MP, Pauwels R, Meijer DK.

J Pept Sci. 1999 Dec;5(12):563-76.

PMID:
10628656
17.

Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation.

Wachtfogel YT, Kettner C, Hack CE, Nuijens JH, Reilly TM, Knabb RM, Kucich U, Niewiarowski S, Edmunds LH Jr, Colman RW.

Thromb Haemost. 1998 Oct;80(4):686-91.

PMID:
9798991
18.

Role of the first N-terminal basic cluster of human lactoferrin (R2R3R4R5) in the interactions with the Jurkat human lymphoblastic T-cells.

Legrand D, van Berkel PH, Salmon V, van Veen HA, Slomianny MC, Nuijens JH, Spik G.

Adv Exp Med Biol. 1998;443:49-55.

PMID:
9781342
19.

Characterization of a hemoglobin protease secreted by the pathogenic Escherichia coli strain EB1.

Otto BR, van Dooren SJ, Nuijens JH, Luirink J, Oudega B.

J Exp Med. 1998 Sep 21;188(6):1091-1103.

20.

The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells.

Legrand D, van Berkel PH, Salmon V, van Veen HA, Slomianny MC, Nuijens JH, Spik G.

Biochem J. 1997 Nov 1;327 ( Pt 3):841-6.

21.

High-level expression of bovine alpha s1-casein in milk of transgenic mice.

Rijnkels M, Kooiman PM, Platenburg GJ, van Dixhoorn M, Nuijens JH, de Boer HA, Pieper FR.

Transgenic Res. 1998 Jan;7(1):5-14.

PMID:
9556911
22.

N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA.

van Berkel PH, Geerts ME, van Veen HA, Mericskay M, de Boer HA, Nuijens JH.

Biochem J. 1997 Nov 15;328 ( Pt 1):145-51.

23.

Characterization of recombinant human lactoferrin secreted in milk of transgenic mice.

Nuijens JH, van Berkel PH, Geerts ME, Hartevelt PP, de Boer HA, van Veen HA, Pieper FR.

J Biol Chem. 1997 Mar 28;272(13):8802-7.

24.

Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.

van Berkel PH, van Veen HA, Geerts ME, de Boer HA, Nuijens JH.

Biochem J. 1996 Oct 1;319 ( Pt 1):117-22.

25.

Structure and biological actions of lactoferrin.

Nuijens JH, van Berkel PH, Schanbacher FL.

J Mammary Gland Biol Neoplasia. 1996 Jul;1(3):285-95. Review.

PMID:
10887502
27.

Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor.

Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, ten Cate H, Hack CE.

Blood. 1995 Mar 15;85(6):1517-26.

28.

Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation.

Wachtfogel YT, Hack CE, Nuijens JH, Kettner C, Reilly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U, et al.

Am J Physiol. 1995 Mar;268(3 Pt 2):H1352-7.

PMID:
7535008
29.

Alpha 1-antitrypsin Pittsburgh (Met358-->Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation.

Wachtfogel YT, Bischoff R, Bauer R, Hack CE, Nuijens JH, Kucich U, Niewiarowski S, Edmunds LH Jr, Colman RW.

Thromb Haemost. 1994 Dec;72(6):843-7.

PMID:
7740452
30.

Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils.

de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, Roos D, van Oers RH, von dem Borne AE.

Blood. 1994 Dec 1;84(11):3885-94.

31.

Lactoferrin is a lipid A-binding protein.

Appelmelk BJ, An YQ, Geerts M, Thijs BG, de Boer HA, MacLaren DM, de Graaff J, Nuijens JH.

Infect Immun. 1994 Jun;62(6):2628-32.

32.

Expression of human lactoferrin in milk of transgenic mice.

Platenburg GJ, Kootwijk EP, Kooiman PM, Woloshuk SL, Nuijens JH, Krimpenfort PJ, Pieper FR, de Boer HA, Strijker R.

Transgenic Res. 1994 Mar;3(2):99-108.

PMID:
8193642
33.

The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.

Eldering E, Huijbregts CC, Nuijens JH, Hack CE.

Behring Inst Mitt. 1993 Dec;(93):125-30. No abstract available.

PMID:
8172559
34.

Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Eldering E, Huijbregts CC, Nuijens JH, Verhoeven AJ, Hack CE.

J Clin Invest. 1993 Mar;91(3):1035-43.

35.

Proteolytic inactivation of alpha 1-antitrypsin and alpha 1-antichymotrypsin by neutrophils in arthritic joints.

Abbink JJ, Kamp AM, Nuijens JH, Swaak TJ, Hack CE.

Arthritis Rheum. 1993 Feb;36(2):168-80.

PMID:
8431205
36.

Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.

Abbink JJ, Kamp AM, Nuijens JH, Erenberg AJ, Swaak AJ, Hack CE.

Ann Rheum Dis. 1992 Oct;51(10):1123-8.

37.

Interleukin-8 in sepsis: relation to shock and inflammatory mediators.

Hack CE, Hart M, van Schijndel RJ, Eerenberg AJ, Nuijens JH, Thijs LG, Aarden LA.

Infect Immun. 1992 Jul;60(7):2835-42.

39.

C1-esterase inhibitor substitution in sepsis.

Hack CE, Voerman HJ, Eisele B, Keinecke HO, Nuijens JH, Eerenberg AJ, Ogilvie A, Strack van Schijndel RJ, Delvos U, Thijs LG.

Lancet. 1992 Feb 8;339(8789):378. No abstract available.

PMID:
1346464
40.

Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis.

Nuijens JH, Abbink JJ, Wachtfogel YT, Colman RW, Eerenberg AJ, Dors D, Kamp AJ, Strack van Schijndel RJ, Thijs LG, Hack CE.

J Lab Clin Med. 1992 Feb;119(2):159-68.

PMID:
1740629
41.

Predominant role of neutrophils in the inactivation of alpha 2-macroglobulin in arthritic joints.

Abbink JJ, Kamp AM, Nieuwenhuys EJ, Nuijens JH, Swaak AJ, Hack CE.

Arthritis Rheum. 1991 Sep;34(9):1139-50.

PMID:
1718287
42.

Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock.

Hack CE, Wagstaff J, Strack van Schijndel RJ, Eerenberg AJ, Pinedo HM, Thijs LG, Nuijens JH.

Thromb Haemost. 1991 May 6;65(5):497-503.

PMID:
1871710
43.

Quantification of functional and inactivated alpha 2-macroglobulin in sepsis.

Abbink JJ, Nuijens JH, Eerenberg AJ, Huijbregts CC, Strack van Schijndel RJ, Thijs LG, Hack CE.

Thromb Haemost. 1991 Jan 23;65(1):32-9.

PMID:
1708920
44.

Soluble Fc gamma receptor III in human plasma originates from release by neutrophils.

Huizinga TW, de Haas M, Kleijer M, Nuijens JH, Roos D, von dem Borne AE.

J Clin Invest. 1990 Aug;86(2):416-23.

45.

[Serine protease inhibitors (serpins); regulators of coagulation and inflammation reactions with therapeutic potential].

Hack CE, Abbink JJ, Nuijens JH.

Ned Tijdschr Geneeskd. 1990 May 26;134(21):1035-9. Review. Dutch. No abstract available.

PMID:
2195358
46.

Methylprednisolone induces activation of the contact system in a dose-dependent manner. An in vitro study.

Roeise O, Nuijens JH, Hack CE, Bouma BN, Stadaas JO, Aasen AO.

Thromb Res. 1990 Mar 15;57(6):877-88.

PMID:
2382256
47.

Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.

Thijs LG, Hack CE, Strack van Schijndel RJ, Nuijens JH, Wolbink GJ, Eerenberg-Belmer AJ, Van der Vall H, Wagstaff J.

J Immunol. 1990 Mar 15;144(6):2419-24.

PMID:
2313099
48.

Phosphatidylinositol-linked FcRIII mediates exocytosis of neutrophil granule proteins, but does not mediate initiation of the respiratory burst.

Huizinga TW, Dolman KM, van der Linden NJ, Kleijer M, Nuijens JH, von dem Borne AE, Roos D.

J Immunol. 1990 Feb 15;144(4):1432-7.

PMID:
2137491
49.

A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients.

Hack CE, Nuijens JH, Strack van Schijndel RJ, Abbink JJ, Eerenberg AJ, Thijs LG.

Intensive Care Med. 1990;16 Suppl 3:S187-91. Review.

PMID:
2289988
50.

Increased plasma levels of interleukin-6 in sepsis.

Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA.

Blood. 1989 Oct;74(5):1704-10.

Supplemental Content

Loading ...
Support Center